MedTrace Logo

The Role of Preoperative HALP Score in Differentiating Complicated Acute Appendicitis

NCT07002671 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 411

Last updated 2025-06-26

No results posted yet for this study

Summary

Acute abdomen is a frequently encountered clinical condition that can be fatal if not diagnosed early. Acute appendicitis is one of the causes of acute abdomen and is the most common clinical condition leading to acute abdomen worldwide. Therefore, early diagnosis is crucial. Delays in diagnosis can lead to the complication of appendicitis and an increase in its complications, further worsening the clinical picture and raising morbidity and mortality rates.

In patients diagnosed with acute appendicitis, distinguishing between complicated and uncomplicated appendicitis is vital for treatment planning. The evaluation of patients' laboratory and radiological findings are widely used methods in clinical practice for this differentiation.

Recent studies have shown the HALP score has become a new prognostic biomarker in the literature, used to predict a range of clinical outcomes in various neoplasms. To date, the HALP score has been used to evaluate outcomes and prognosis in gastric, colorectal, bladder, prostate, and other cancers, as well as in many other diseases.

The purpose of this study is to determine the clinical impact of using the preoperatively calculated HALP score, derived from blood parameters, in the diagnosis, detection, and treatment of complicated acute appendicitis cases in the preoperative period without the need for additional diagnostic methods.

Conditions

  • Acute Appendicitis
  • Acute Appendicitis Without Peritonitis
  • Acute Appendicitis With Appendix Abscess
  • Acute Appendicitis With Rupture

Interventions

PROCEDURE

Appendectomy

Appendectomy (Laparoscopic or conventional open surgery)

DIAGNOSTIC_TEST

blood sampling

Blood samples, in the preoperative period, routinely collected from the patients of acute appendicitis cases

Sponsors & Collaborators

  • Elazıg Fethi Sekin Sehir Hastanesi

    collaborator OTHER

  • Kahramanmaras Sutcu Imam University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2025-01-01
Completion
2025-05-20

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07002671 on ClinicalTrials.gov